Literature DB >> 18159466

Antimicrobials in acute exacerbations of chronic obstructive pulmonary disease - An analysis of the time to next exacerbation before and after the implementation of standing orders.

Rob D Goddard1, Shelly A McNeil, Kathryn L Slayter, R Andrew McIvor.   

Abstract

OBJECTIVE: To compare the mean time to next exacerbation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) before and after the implementation of standing orders.
SETTING: Tertiary care hospital, Halifax, Nova Scotia, Canada. POPULATION STUDIED: The records of 150 patients were analyzed, 76 were in the preimplementation group, 74 in the postimplementation group. INTERVENTION: The management and outcomes of patients admitted with an acute exacerbation of COPD before and after the implementation of standing orders were compared.
DESIGN: A retrospective chart review. MAIN
RESULTS: THERE WAS NO DIFFERENCE IN THE MEAN TIME TO NEXT EXACERBATION BETWEEN TREATMENT GROUPS (PREIMPLEMENTATION GROUP: 310 days, postimplementation group: 289 days, P=0.53). Antibiotics were used in 90% of the cases (preimplementation group: 87%, postimplementation group: 93%). The postimplementation group had a 20% increase in the use of first-line agents over the preimplementation group. Overall, first-line agents represented only 37% of the antibiotic courses.
CONCLUSIONS: The implementation of standing orders encouraged the use of first-line agents but did not influence subsequent symptom resolution, length of hospital stay, or the infection-free interval in patients with acute exacerbations of COPD.

Entities:  

Keywords:  Antibiotics; Chronic obstructive pulmonary disease; Exacerbation

Year:  2003        PMID: 18159466      PMCID: PMC2094950          DOI: 10.1155/2003/392617

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  26 in total

1.  Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study.

Authors:  L Allegra; F Blasi; B de Bernardi; R Cosentini; P Tarsia
Journal:  Pulm Pharmacol Ther       Date:  2001       Impact factor: 3.410

2.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

3.  Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice.

Authors:  A F Jørgensen; J Coolidge; P A Pedersen; K P Petersen; S Waldorff; E Widding
Journal:  Scand J Prim Health Care       Date:  1992-03       Impact factor: 2.581

4.  Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis.

Authors:  A Pines; H Raafat; J S Greenfield; W D Linsell; M E Solari
Journal:  Br J Dis Chest       Date:  1972-04

5.  Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis.

Authors:  P C Elmes; T K King; J H Langlands; J A Mackay; W F Wallace; O L Wade; T S Wilson
Journal:  Br Med J       Date:  1965-10-16

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

7.  Acute exacerbation of COPD: factors associated with poor treatment outcome.

Authors:  N A Dewan; S Rafique; B Kanwar; H Satpathy; K Ryschon; G S Tillotson; M S Niederman
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

Review 8.  Infectious etiology of acute exacerbations of chronic bronchitis.

Authors:  S Sethi
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

9.  Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

Authors:  S Chodosh; J McCarty; S Farkas; M Drehobl; R Tosiello; M Shan; L Aneiro; S Kowalsky
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

10.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force.

Authors:  N M Siafakas; P Vermeire; N B Pride; P Paoletti; J Gibson; P Howard; J C Yernault; M Decramer; T Higenbottam; D S Postma
Journal:  Eur Respir J       Date:  1995-08       Impact factor: 16.671

View more
  1 in total

1.  Antibiotics for exacerbations of chronic obstructive pulmonary disease.

Authors:  Daniela J Vollenweider; Anja Frei; Claudia A Steurer-Stey; Judith Garcia-Aymerich; Milo A Puhan
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.